Table S4 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Year: 2023
Type: other
Abstract: Adverse events, regardless of study drug relationship, by preferred term and maximum grade (>20% overall)
Authors: Mark W. Kieran, Birgit Geoerger, Ira J. Dunkel, Alberto Broniscer, Darren Hargrave, Pooja Hingorani, Isabelle Aerts, Anne-Isabelle Bertozzi, Kenneth J. Cohen, Trent R. Hummel, Violet Shen, Eric Bouffet, Christine A. Pratilas, Andrew D.J. Pearson, Lillian Tseng, Noelia Nebot, Steven Green, Mark W. Russo, James A. Whitlock
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361887791